摘要
目的:分析达格列净对不同左心室射血分数心衰患者疗效及预后影响.方法:选取 2022年 10月至 2023年 11月收入的 200例不同左心室射血分数心衰患者,根据左心室射血分数将其分为＞40%组和≤40%组.两组患者在常规治疗基础上均使用达格列净.3 个月后评估肾功能、BNP 水平等指标,并随访 6 个月.结果:两组在达格列净治疗后,肾功能、BNP水平、心脏结构参数、BMI、6 分钟步行距离、静息心率以及各类并发症发生率等均有显著改善(P<0.05).且两组治疗后各项指标相近(P＞0.05).结论:达格列净在治疗各种左心室射血分数的心衰患者时均表现良好,且疗效和预后不受射血分数影响.
Abstract
Objective:To analyze the efficacy and prognostic impact of dapagliflozin on heart failure patients with different left ventricular ejection fractions.Method:200 heart failure patients with varying left ventricular ejection fractions,admitted between October 2022 to November 2023,were selected and categorized into two groups based on their ejection fractions:>40%and≤40%.Both groups received dapagliflozin alongside conventional treatment.Various parameters,including renal function and BNP levels,were assessed after 3 months,followed by a 6-month follow-up.Results:Significant improvements were observed in renal function,BNP levels,cardiac structural parameters,BMI,6-minute walk distance,resting heart rate,and the incidence of various complications in both groups after dapagliflozin treatment(P<0.05).The post-treatment indicators were similar between the two groups(P>0.05).Conclusion:Dapagliflozin demonstrates effective treatment for heart failure patients across various left ventricular ejection fractions,with its efficacy and prognosis unaffected by the ejection fraction.
国家科技期刊平台
NSTL
万方数据